476 related articles for article (PubMed ID: 10801247)
1. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
[TBL] [Abstract][Full Text] [Related]
2. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
3. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
4. Effects of bioflavonoids on hepatic P450 activities.
Obermeier MT; White RE; Yang CS
Xenobiotica; 1995 Jun; 25(6):575-84. PubMed ID: 7483658
[TBL] [Abstract][Full Text] [Related]
5. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
Ito K; Ogihara K; Kanamitsu S; Itoh T
Drug Metab Dispos; 2003 Jul; 31(7):945-54. PubMed ID: 12814973
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
[TBL] [Abstract][Full Text] [Related]
7. Alprazolam-ritonavir interaction: implications for product labeling.
Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
[TBL] [Abstract][Full Text] [Related]
8. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice.
Greenblatt DJ; von Moltke LL; Harmatz JS; Chen G; Weemhoff JL; Jen C; Kelley CJ; LeDuc BW; Zinny MA
Clin Pharmacol Ther; 2003 Aug; 74(2):121-9. PubMed ID: 12891222
[TBL] [Abstract][Full Text] [Related]
9. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
[TBL] [Abstract][Full Text] [Related]
10. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.
Ring BJ; Patterson BE; Mitchell MI; Vandenbranden M; Gillespie J; Bedding AW; Jewell H; Payne CD; Forgue ST; Eckstein J; Wrighton SA; Phillips DL
Clin Pharmacol Ther; 2005 Jan; 77(1):63-75. PubMed ID: 15637532
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies.
Hamaoka N; Oda Y; Hase I; Asada A
Br J Anaesth; 2001 Apr; 86(4):540-4. PubMed ID: 11573629
[TBL] [Abstract][Full Text] [Related]
12. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
13. Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics.
Rogers JF; Morrison AL; Nafziger AN; Jones CL; Rocci ML; Bertino JS
Clin Pharmacol Ther; 2002 Dec; 72(6):711-7. PubMed ID: 12496752
[TBL] [Abstract][Full Text] [Related]
14. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
16. Plasma concentrations of active simvastatin acid are increased by gemfibrozil.
Backman JT; Kyrklund C; Kivistö KT; Wang JS; Neuvonen PJ
Clin Pharmacol Ther; 2000 Aug; 68(2):122-9. PubMed ID: 10976543
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
[TBL] [Abstract][Full Text] [Related]
18. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
[TBL] [Abstract][Full Text] [Related]
19. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
20. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats.
Hidaka M; Okumura M; Fujita K; Ogikubo T; Yamasaki K; Iwakiri T; Setoguchi N; Arimori K
Drug Metab Dispos; 2005 May; 33(5):644-8. PubMed ID: 15673597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
